This recent study investigated whether [18F]2-fluoro-2-deoxy-D-glucose (FDG-PET) imaging may better predict long-term outcomes compared with standard computed tomography (CT) response criteria in metastatic melanoma. The study concludes that PET may have utility in predicting long-term benefit and help guide discontinuation of therapy.
Authors of this recent study found two loci potentially associated with melanoma-specific survival (MSS), and evidence that increased germline genetic susceptibility to develop cutaneous melanoma may be associated with improved MSS.
The objective of this recent study was to review and assess the consistency of recommendations in relevant guidance documents in Australia and New Zealand regarding the risks and benefits of sun exposure. The study concludes that better and more consistent guidance and advice about the risk and benefits of sun exposure is required.
This recent study explains that the available evidence on national incidence rates is out of date and of moderate quality, but indicates very high rates of keratinocyte cancer in Australia. Authors recommend that population-based cancer registries work towards statutory notification and routine reporting of keratinocyte cancer in Australia.
According to this recent study, regulation is essential to ensure high-quality, safe and effective sunscreen products are available to the Australian population. There is an important role for governments to put in place skin cancer prevention policies and long-term funding arrangements.
The objective of this recent study was to detail the approach and progress being made by the Shade Working Goup (SWG) across health and the built environment to embed natural and built quality shade provision in places used by the community in New South Wales (NSW), Australia.The study concludes that the ways of working adopted by the SWG demonstrate effective collaborative principles for others to use to positively impact accepted practice across health and the built environment.
According to this recent study, the future of skin cancer early detection in Australia and internationally may incorporate features such as a more structured approach to skin cancer risk assessment using online risk calculators and invitations to screen, consumer-driven melanoma surveillance, and new technologies for diagnosis and monitoring of lesions. High-quality research evidence is being generated across multiple research programs, and is essential to underpin any changes to policy and practice in skin cancer early detection.
The randomized, double-blind STARBOARD trial aims to evaluate efficacy and safety of encorafenib, binimetinib, and pembrolizumab in treatment-naive patients with metastatic or unresectable locally advanced BRAF V600-mutant melanoma in comparison to pembrolizumab.
According to this recent research, the estimated total cost to New Zealand in 2021 for new patients with melanoma was NZ$51.2 m, and for keratinocyte skin cancer (KCs), was NZ$129.4 m, with a total combined cost of NZ$180.5 m. These up-to-date national healthcare costs of melanoma and KC in Australia and New Zealand accentuate the savings potential of successful prevention strategies for skin cancer.
Findings of this recent study highlight the need for increased access to sun-protective clothing and sunscreen that is suitable for wearing when working on farms, complemented by culturally appropriate health education messaging, to encourage more farmers to perform SunSmart behaviours.